Madrigal Pharmaceuticals
$499.40Change from previous close: −0.06%Absolute change: −$0.31
At a glance
- Revenue growth
- +432.05%
- 2025 vs 2024
- Net margin
- -30.1%
- 2024: -258.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total assets | 1,245 | 1,227 | 1,260 | 1,362 | 1,015 |
| Current assets | 1,199 | 1,182 | 1,246 | 1,347 | 1,003 |
| Cash and equivalents | 293 | 227 | 199 | 296 | 186 |
| Short-term investments | 546 | 586 | 785 | 814 | 611 |
| Receivables | 192 | 187 | 134 | 113 | 79.2 |
| Inventory | 99.4 | 112 | 74.8 | 69.3 | 63.5 |
| Net property, plant and equipment | 17.2 | 14.2 | 6.4 | 8.3 | 7.5 |
| Current liabilities | 374 | 338 | 310 | 391 | 197 |
| Accounts payable | 34.5 | 60.8 | 48.9 | 44.9 | 38.0 |
| Long-term debt | 341 | 340 | 340 | 340 | 118 |
| Total debt | 348 | 347 | 348 | 346 | 124 |
| Total liabilities | 721 | 684 | 657 | 737 | 319 |
| Total equity (incl. minority) | 524 | 543 | 603 | 626 | 696 |
| Retained earnings | -2,243 | -2,185 | -2,090 | -2,032 | -1,918 |